This biotech name is one of Jim Cramer's favorite stocks and he thinks it can go even higher

rose Monday after the Food and Drug Administration approved a higher-dose formulation of Eylea, the company's macular degeneration treatment.email newsletter for freeCNBC's Jim Cramer said on"Squawk on the Street" that Regeneron is one of his favorite health-care names, describing Eylea as"a remarkable drug for macular degeneration.

"I think being up [11 points] is not enough," Jim said as shares traded $11 higher. "I think it's going to be worth more." The CNBC Investing Club with Jim Cramer doesn't own Regeneron. But the Club does own health-care stocks, including, which has been soaring to record high after record high. Cramer's case for Lilly centers on its new diabetes drug, which is expected to get regulatory approval to also treat obesity. Lilly also has an Alzheimer's drug in FDA review.

Россия Последние новости, Россия Последние новости

Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей

Jim Cramer's top 10 things to watch in the stock market MondayStocks edge up in premarket trading Monday, following three-consecutive weeks of losses, as the market looks to Nvidia's (NVDA) quarterly report.
Источник: CNBC - 🏆 12. / 72 Прочитайте больше »

Here are 14 stocks Jim Cramer is watching, including Amazon, Salesforce, Goldman SachsHere are some of the tickers on my radar for Monday, Aug. 21 taken directly from my reporter's notebook.
Источник: CNBC - 🏆 12. / 72 Прочитайте больше »

Jim Cramer says this surging cybersecurity is gaining market share and proving doubters wrongPalo Alto Networks is a compelling stock to own as it gains share in the increasingly important cybersecurity market, CNBC’s Jim Cramer said.
Источник: NBCLA - 🏆 319. / 59 Прочитайте больше »